Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
11,274.20569.4
Stock Analysis, IPO, Mutual Funds, Bonds & More

USFDA issues 12 observations for 3 Biocon units in Malaysia

US health regulator has issued 12 observations after the inspection of three of Biocon's units in Malaysia.

PTI|
Jul 08, 2019, 04.06 PM IST
0Comments
Agencies
Biocon---Agencies
As per the USFDA, the Form 483 notifies the company's management of objectionable conditions after the conclusion of an inspection.
NEW DELHI: Biotechnology major Biocon Monday said US health regulator has issued 12 observations after the inspection of three of its units in Malaysia.

Biocon Sdn Bhd's insulin glargine drug substance, drug product and device assembly facilities in Malaysia underwent a pre-approval inspection by the USFDA between June 24 and July 5, 2019, Biocon said in a filing to BSE.

"The inspection across these three units concluded with 12 observations issued on the Form 483," a company spokesperson said in a statement.

As per the USFDA, the Form 483 notifies the company's management of objectionable conditions after the conclusion of an inspection.

"We will respond to the FDA with a corrective and preventive action plan and are confident of addressing these observations expeditiously," the statement said.

The company does not expect any change to its commercialisation plans for insulin glargine in the US, it added.

"Biocon remains committed to global standards of quality and compliance," the statement said.

The company, however, did not provide any details about the observations made by the US regulator.

Shares of Biocon were trading at Rs 242.90 per scrip on BSE, up 1.31 per cent from its previous close.

Also Read

USFDA concludes inspection of Unichem Lab's Roha facility

USFDA finds Salmonella bacteria in MDH sambar masala

Inspection of Unichem's Kolhapur facility by USFDA completed without observations

Lupin gets warning letter from USFDA for Mandideep facility

USFDA completes inspection of Strides Pharma Bengaluru plant

Comments
Add Your Comments
Commenting feature is disabled in your country/region.
Download The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.

Other useful Links


Follow us on


Download et app


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service